Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Phase 4UnknownNCT02027064

Peking University People's Hospital40 enrolled

Overview

molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion. Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients. the study is to evaluate the safety and efficacy of interferon for the intervention of molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Myeloid Leukemia

Interventions

Interferon-alphaDRUG

Eligibility

Sex: ALLMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * high risk t (8; 21) AML * molecular relapse after allo-SCT Exclusion Criteria: * active graft-versus-host disease * uncontrolled severe infection * organ function failure

Locations (1)

Peking University People's Hospital

Beijing, China

RECRUITING

Outcomes

Primary Outcomes

relapse rate

number of participants with morphologic relapse at one year

Time frame: participants will be followed for an expected average of 365 days

Central Contacts

yu wang, M.D.

CONTACT

861088326666 ywyw3172@sina.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.